Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Niagen Bioscience, Inc. (NAGE)

Compare
6.57
+0.03
+(0.54%)
As of 10:53:32 AM EDT. Market Open.
Loading Chart for NAGE
  • Previous Close 6.54
  • Open 6.54
  • Bid 6.62 x 200
  • Ask 6.51 x 200
  • Day's Range 6.51 - 6.74
  • 52 Week Range 2.31 - 9.18
  • Volume 116,704
  • Avg. Volume 877,383
  • Market Cap (intraday) 511.209M
  • Beta (5Y Monthly) 2.18
  • PE Ratio (TTM) 59.77
  • EPS (TTM) 0.11
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.82

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

www.niagenbioscience.com

104

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NAGE

View More

Performance Overview: NAGE

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NAGE
23.82%
S&P 500 (^GSPC)
10.33%

1-Year Return

NAGE
65.62%
S&P 500 (^GSPC)
5.01%

3-Year Return

NAGE
207.24%
S&P 500 (^GSPC)
20.07%

5-Year Return

NAGE
75.80%
S&P 500 (^GSPC)
83.47%

Compare To: NAGE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NAGE

View More

Valuation Measures

Annual
As of 4/16/2025
  • Market Cap

    508.49M

  • Enterprise Value

    466.63M

  • Trailing P/E

    59.45

  • Forward P/E

    54.64

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.13

  • Price/Book (mrq)

    11.03

  • Enterprise Value/Revenue

    4.69

  • Enterprise Value/EBITDA

    50.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.59%

  • Return on Assets (ttm)

    7.84%

  • Return on Equity (ttm)

    22.94%

  • Revenue (ttm)

    99.6M

  • Net Income Avi to Common (ttm)

    8.55M

  • Diluted EPS (ttm)

    0.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.51M

  • Total Debt/Equity (mrq)

    5.75%

  • Levered Free Cash Flow (ttm)

    9.61M

Research Analysis: NAGE

View More

Company Insights: NAGE

Research Reports: NAGE

View More

People Also Watch